NRD
PLRX icon

Nebula Research & Development’s Pliant Therapeutics PLRX Stock Holding History

Nebula Research & Development’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-24,904
Closed -$268K – 1124
2024
Q2 		$268K Buy
24,904
+7,254
+41% +$93.5K 0.04% 636
2024
Q1 		$263K Buy
+17,650
New +$291K 0.06% 578

Other funds holding PLRX

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Nebula Research & Development's PLRX Position: Q3 2024 in Review

Nebula Research & Development sold out of Pliant Therapeutics (PLRX) in Q3 2024, closing a stake of 24,904 shares — an estimated $268K sold.

Nebula Research & Development first reported a position in PLRX in Q1 2024 and held it in 2 quarters. The position peaked at $268K in Q2 2024. 151 funds tracked by Wall St. Rank hold PLRX as of Q3 2024.

  • Nebula Research & Development reported no remaining Pliant Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Nebula Research & Development sold 24,904 Pliant Therapeutics shares in Q3 2024, an estimated $268K.
  • Nebula Research & Development first reported a position in Pliant Therapeutics in Q1 2024 and held it in 2 quarters.
  • Nebula Research & Development's Pliant Therapeutics position peaked at $268K in Q2 2024.
  • 151 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2024.

Based on Nebula Research & Development's 13F filing for Q3 2024, filed 14 Nov 2024.